inex to expand ovplex distribution to malaysia

HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
INEX to expand OvPlex ™ distribution to Malaysia
7 October 2011: HealthLinx Limited (ASX:HTX) with distribution partners INEX innovations
exchange will begin selling OvPlex™ in Malaysia on 10 October 2011. OvPlex™ will be
available in Kuala Lumpur from Monday, with extension of distribution to take place through all
major Malaysian cities in January 2012.
This rapid expansion of jurisdictions in Asia in which OvPlex™ is available is prompted by
excellent market acceptance and growth in Singapore, where it has been on the market since
October 2010. Since this time, INEX has exceeded expected sales targets by approximately
30% or 200 units.
Both INEX and HealthLinx expect sales within Singapore and Malaysia to grow to over 150
units per month over the next 6-12 months. The two companies are also exploring the
opportunity of obtaining private insurance reimbursement on the test which should only further
increase sales.
“This expansion is an excellent result for women in Malaysia who now have access to
OvPlex™,” said managing director Nick Gatsios. “As a company we are excited with INEX’s
proactive expansion strategies and management of both companies are working very closely to
ensure further expansion occurs in a seamless, cohesive and timely manner.”
Plans to expand into other jurisdictions to which INEX has an option in their distribution
agreement, including Indonesia and India, will be announced in due course.
Enquiries
Nick Gatsios (HealthLinx Limited) +61 3 9208 4200
Rudi Michelson (Monsoon Communications) +61 3 9620 3333
About HealthLinx Limited (ASX:HTX)
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial
targets are for diseases with high fatality:
• Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
• Prostate cancer targeting US$350m pa market
A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.
HealthLinx has commenced the second larger study for OvPlexTM aiming to prove a diagnostic accuracy of over 97 per
cent for early stage ovarian cancer. This larger study is based on 1150 new samples using existing OvPlex™ biomarkers
and including two novel biomarkers AGR2 and HTX010. The study will be a robust comparison of sensitivity and
specificity especially for early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex™
as the world’s most accurate and efficient ovarian cancer diagnostic.
The second study is partially funded with $750,000 from the Victorian Government Victoria’s Science Agenda Investment